Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Alnylam Pharmaceuticals is conducting a Phase 1 study titled A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma. The study aims to assess the safety, tolerability, and antitumor activity of ALN-BCAT, both alone and with pembrolizumab, in patients with advanced stages of liver cancer. This research is significant as it explores new treatment avenues for a challenging condition.
Intervention/Treatment: The study tests ALN-BCAT, an experimental drug administered via intravenous infusion, both as a standalone treatment and in combination with pembrolizumab, another intravenous drug. The goal is to find the optimal dose and evaluate its effectiveness in treating liver cancer.
Study Design: This interventional study is non-randomized and follows a parallel assignment model without masking. The primary purpose is treatment-focused, aiming to determine the best dose and assess the treatment’s impact on tumor activity.
Study Timeline: The study began on September 13, 2024, with the latest update submitted on August 25, 2025. These dates are crucial as they mark the study’s progress and provide a timeline for potential results that could influence treatment options.
Market Implications: This study update could positively impact Alnylam Pharmaceuticals’ stock performance by showcasing their commitment to innovative cancer treatments. Successful outcomes may enhance investor confidence and position the company favorably against competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.